rs141443652
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The ENST00000266732.8(TMPO):c.1277C>T(p.Pro426Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00173 in 1,614,072 control chromosomes in the GnomAD database, including 7 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
ENST00000266732.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TMPO | NM_001032283.3 | c.565+1696C>T | intron_variant | ENST00000556029.6 | NP_001027454.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TMPO | ENST00000556029.6 | c.565+1696C>T | intron_variant | 1 | NM_001032283.3 | ENSP00000450627 |
Frequencies
GnomAD3 genomes AF: 0.00133 AC: 203AN: 152120Hom.: 1 Cov.: 33
GnomAD3 exomes AF: 0.00125 AC: 313AN: 251358Hom.: 0 AF XY: 0.00120 AC XY: 163AN XY: 135852
GnomAD4 exome AF: 0.00177 AC: 2593AN: 1461834Hom.: 6 Cov.: 32 AF XY: 0.00170 AC XY: 1233AN XY: 727222
GnomAD4 genome AF: 0.00133 AC: 203AN: 152238Hom.: 1 Cov.: 33 AF XY: 0.00130 AC XY: 97AN XY: 74432
ClinVar
Submissions by phenotype
not provided Benign:4
Likely benign, criteria provided, single submitter | research | Biesecker Lab/Clinical Genomics Section, National Institutes of Health | Jun 24, 2013 | - - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | May 01, 2024 | TMPO: BP4, BS1 - |
Likely benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Oct 02, 2019 | - - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Feb 15, 2022 | This variant is associated with the following publications: (PMID: 24375709, 23861362, 28074886) - |
not specified Uncertain:1Benign:2
Uncertain significance, no assertion criteria provided | clinical testing | Stanford Center for Inherited Cardiovascular Disease, Stanford University | Mar 20, 2014 | Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. p.Pro426Leu (P426L; c.1277 C>T) in the TMPO gene We consider this a Variant of Unknown Significance (VUS)-Probably Benign, given that it has only been reported in the general population and not in any patients with cardiomyopathy. Furthermore, the TMPO gene has been associated in just one family with a disease of the heart muscle known as dilated cardiomyopathy (DCM). It might rightly be called a “gene of uncertain significance” given that only this one variant in one family has been reported: Arg690Cys in two brothers with DCM (Taylor et al. 2005; HGMD). That same variant, Arg690Cys, is present in the NHLBI Exome Sequencing Project (ESP) dataset in 4 Caucasian and 4 African-American individuals, raising the possibility that it is a rare benign variant. The specific variant found in our patient Pro426Leu, has not been reported in the scientific literature as a disease-causing mutation nor as a benign polymorphism to our knowledge. This is a conservative amino acid substitution in which a non-polar Proline is replaced by a non-polar Leucine at a residue that is conserved across species. In silico analysis with PolyPhen-2 predicts the variant to be “probably damaging” with a score of 1.0. The Pro426Leu variant has been observed in 16 out of ~7500 individuals from population datasets. It was found in 2 individuals from Finland in the 1000 Genomes data. It was also found in 13 Caucasian and 1 African-American individuals in the NHLBI Exome Sequencing Project (ESP) dataset, which currently includes variant calls on ~4300 Caucasian and ~2200 African American individuals (as of March 20, 2014). This represents an allele frequency of 0.15% among Caucasians in the ESP. The phenotype of the ESP individuals is not publicly available, however the cohorts that were merged to create this dataset were all either general population samples or samples recruited for common cardiovascular disease such as hypertension. - |
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 12, 2018 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 12, 2022 | - - |
Dilated cardiomyopathy 1T Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | May 26, 2016 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | Sep 21, 2015 | - - |
Primary dilated cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Phosphorus, Inc. | Aug 01, 2017 | - - |
TMPO-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 03, 2021 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Loeys-Dietz syndrome 2 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | - - |
Amyloidosis;C0349788:Arrhythmogenic right ventricular cardiomyopathy Benign:1
Benign, criteria provided, single submitter | clinical testing | Center for Advanced Laboratory Medicine, UC San Diego Health, University of California San Diego | Jul 13, 2018 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at